請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92663
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林峯輝 | zh_TW |
dc.contributor.advisor | Feng-Huei Lin | en |
dc.contributor.author | 林意文 | zh_TW |
dc.contributor.author | Yi-Wen Lin | en |
dc.date.accessioned | 2024-05-31T16:06:44Z | - |
dc.date.available | 2024-06-01 | - |
dc.date.copyright | 2024-05-31 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-12-12 | - |
dc.identifier.citation | 1. Alzheimer, A., et al., An English translation of Alzheimer's 1907 paper," Uber eine eigenartige Erkankung der Hirnrinde". Clinical anatomy (New York, NY), 1995. 8(6): p. 429-431.
2. Krslovic, K., Dementia and Socioeconomic Status: A proposal on the effects of occupation level on cognitive decline. 2023. 3. Yong, K., et al., Posterior cortical atrophy, in: World Alzheimer Report 2022 Life after diagnosis: Navigating treatment, care and support, pp. 310-312. 2022. 4. Association, A., Alzheimer’s disease facts and figures. Alzheimer's & Dementia, 2019. 15(3): p. 321-387. 5. Rizzi, L., I. Rosset, and M. Roriz-Cruz, Global epidemiology of dementia: Alzheimer’s and vascular types. BioMed research international, 2014. 2014. 6. Ahmad Fazili, N., et al., Therapeutic interventions for the suppression of Alzheimer’s disease: quest for a remedy. Current Drug Metabolism, 2015. 16(5): p. 346-353. 7. Reisberg, B., et al., Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. The Journal of clinical psychiatry, 1987. 48: p. 9-15. 8. McKhann, G.M., et al., The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia, 2011. 7(3): p. 263-269. 9. Sperling, R.A., et al., Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia, 2011. 7(3): p. 280-292. 10. Marei, H.E., et al., Recent perspective about the amyloid cascade hypothesis and stem cell-based therapy in the treatment of alzheimer’s disease. Frontiers in Clinical Drug Research-Alzheimer Disorders. BENTHAM SCIENCE PUBLISHERS, 2016. 11. Puglielli, L., R.E. Tanzi, and D.M. Kovacs, Alzheimer's disease: the cholesterol connection. Nature neuroscience, 2003. 6(4): p. 345-351. 12. Hardy, J. and D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. science, 2002. 297(5580): p. 353-356. 13. Berger-Sweeney, J., The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers. Neuroscience & Biobehavioral Reviews, 2003. 27(4): p. 401-411. 14. Greig, N.H., et al., A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Current medical research and opinion, 2001. 17(3): p. 159-165. 15. Mesulam, M. and C. Geula, Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 1994. 36(5): p. 722-727. 16. Wright, C.I., C. Geula, and M.M. Mesulam, Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 1993. 34(3): p. 373-384. 17. Davies, P. and A. Maloney, Selective loss of central cholinergic neurons in Alzheimer's disease. The Lancet, 1976. 308(8000): p. 1403. 18. Holmes, B.B., et al., Proteopathic tau seeding predicts tauopathy in vivo. Proceedings of the National Academy of sciences, 2014. 111(41): p. E4376-E4385. 19. Asai, H., et al., Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nature neuroscience, 2015. 18(11): p. 1584-1593. 20. Yanamandra, K., et al., Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron, 2013. 80(2): p. 402-414. 21. Braak, H., et al., Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta neuropathologica, 2006. 112(4): p. 389-404. 22. Guerreiro, R., et al., TREM2 variants in Alzheimer's disease. New England Journal of Medicine, 2013. 368(2): p. 117-127. 23. Kumar, A. and A. Singh, A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacological reports, 2015. 67(2): p. 195-203. 24. Glenner, G.G. and C.W. Wong, Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochemical and biophysical research communications, 1984. 122(3): p. 1131-1135. 25. O'brien, R.J. and P.C. Wong, Amyloid precursor protein processing and Alzheimer's disease. Annual review of neuroscience, 2011. 34: p. 185-204. 26. Selkoe, D.J., Alzheimer's disease: genes, proteins, and therapy. Physiological reviews, 2001. 27. Spires-Jones, T.L. and B.T. Hyman, The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron, 2014. 82(4): p. 756-771. 28. Cardona, A.E., et al., Isolation of murine microglial cells for RNA analysis or flow cytometry. Nature protocols, 2006. 1(4): p. 1947-1951. 29. Filiano, A.J., S.P. Gadani, and J. Kipnis, Interactions of innate and adaptive immunity in brain development and function. Brain research, 2015. 1617: p. 18-27. 30. VanItallie, T.B., Alzheimer's disease: Innate immunity gone awry? Metabolism, 2017. 69: p. S41-S49. 31. Yu, Y. and R.D. Ye, Microglial Aβ receptors in Alzheimer’s disease. Cellular and molecular neurobiology, 2015. 35: p. 71-83. 32. Heneka, M.T., D.T. Golenbock, and E. Latz, Innate immunity in Alzheimer's disease. Nature immunology, 2015. 16(3): p. 229-236. 33. Fu, W.-Y., X. Wang, and N.Y. Ip, Targeting neuroinflammation as a therapeutic strategy for Alzheimer’s disease: mechanisms, drug candidates, and new opportunities. ACS chemical neuroscience, 2018. 10(2): p. 872-879. 34. Sierra, A., et al., Microglia derived from aging mice exhibit an altered inflammatory profile. Glia, 2007. 55(4): p. 412-424. 35. Wong, W.T., Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation. Frontiers in cellular neuroscience, 2013. 7: p. 22. 36. Lopes, K.O., D.L. Sparks, and W.J. Streit, Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia, 2008. 56(10): p. 1048-1060. 37. Streit, W.J., Microglial senescence: does the brain's immune system have an expiration date? Trends in neurosciences, 2006. 29(9): p. 506-510. 38. Simard, A.R. and S. Rivest, Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. The FASEB Journal, 2004. 18(9): p. 998-1000. 39. Koenigsknecht, J. and G. Landreth, Microglial phagocytosis of fibrillar β-amyloid through a β1 integrin-dependent mechanism. Journal of Neuroscience, 2004. 24(44): p. 9838-9846. 40. Nimmerjahn, A., F. Kirchhoff, and F. Helmchen, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science, 2005. 308(5726): p. 1314-1318. 41. Tang, Y. and W. Le, Differential roles of M1 and M2 microglia in neurodegenerative diseases. Molecular neurobiology, 2016. 53: p. 1181-1194. 42. Wang, W.-Y., et al., Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Annals of translational medicine, 2015. 3(10). 43. Orihuela, R., C.A. McPherson, and G.J. Harry, Microglial M1/M2 polarization and metabolic states. British journal of pharmacology, 2016. 173(4): p. 649-665. 44. Koenigsknecht-Talboo, J. and G.E. Landreth, Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. Journal of Neuroscience, 2005. 25(36): p. 8240-8249. 45. Pan, S.Y., et al., Tacrine treatment at high dose suppresses the recognition memory in juvenile and adult mice with attention to hepatotoxicity. Basic & clinical pharmacology & toxicology, 2011. 108(6): p. 421-427. 46. Burki, T., Alzheimer's disease research: the future of BACE inhibitors. The Lancet, 2018. 391(10139): p. 2486. 47. Thaisrivongs, D.A., et al., A next generation synthesis of BACE1 inhibitor verubecestat (MK-8931). Organic letters, 2018. 20(6): p. 1568-1571. 48. Neumann, U., et al., The BACE‐1 inhibitor CNP 520 for prevention trials in Alzheimer's disease. EMBO molecular medicine, 2018. 10(11): p. e9316. 49. Lopez, C.L., et al., The Alzheimer’s Prevention Initiative Generation Program: evaluating CNP520 efficacy in the prevention of Alzheimer’s disease. J Prev Alzheimers Dis, 2017. 4(4): p. 242-6. 50. Sampson, E.L., L. Jenagaratnam, and R. McShane, Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Cochrane Database of Systematic Reviews, 2014(2). 51. Leung, K., 1-Deoxy-1-[18F] fluoro-scyllo-inositol. Molecular Imaging and Contrast Agent Database (MICAD)[Internet], 2012. 52. Dong, Y., et al., Drug development for Alzheimer’s disease: microglia induced neuroinflammation as a target? International journal of molecular sciences, 2019. 20(3): p. 558. 53. Godyń, J., et al., Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacological Reports, 2016. 68(1): p. 127-138. 54. Daniels, M.J., et al., Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models. Nature communications, 2016. 7(1): p. 12504. 55. Vlad, S.C., et al., Protective effects of NSAIDs on the development of Alzheimer disease. Neurology, 2008. 70(19): p. 1672-1677. 56. Imbimbo, B.P., An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. Expert opinion on investigational drugs, 2009. 18(8): p. 1147-1168. 57. Medina, M., An overview on the clinical development of tau-based therapeutics. International journal of molecular sciences, 2018. 19(4): p. 1160. 58. Bachurin, S.O., E.V. Bovina, and A.A. Ustyugov, Drugs in clinical trials for Alzheimer's disease: the major trends. Medicinal research reviews, 2017. 37(5): p. 1186-1225. 59. Tlustochowicz, W., et al., Efficacy and safety of subcutaneous and intravenous loading dose regimens of secukinumab in patients with active rheumatoid arthritis: results from a randomized phase II study. The Journal of rheumatology, 2016. 43(3): p. 495-503. 60. Sparrow, C.P., et al., Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arteriosclerosis, thrombosis, and vascular biology, 2001. 21(1): p. 115-121. 61. Alam, J., K. Blackburn, and D. Patrick, Neflamapimod: clinical phase 2b-ready oral small molecule inhibitor of p38alpha to reverse synaptic dysfunction in early Alzheimer’s disease. J. Prev. Alzheimers Dis, 2017. 4(4): p. 273-278. 62. Burstein, A., et al., Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer’s disease. The journal of prevention of Alzheimer's disease, 2018. 5: p. 149-154. 63. Cobb, J., et al. Troglitazone is a peroxisome proliferator activated receptor gamma agonist: A novel mechanism for an antidiabetic agent. in Diabetologia. 1997. SPRINGER VERLAG 175 FIFTH AVE, NEW YORK, NY 10010. 64. Miller, A., Collagen: the organic matrix of bone. Philosophical Transactions of the Royal Society of London. B, Biological Sciences, 1984. 304(1121): p. 455-477. 65. Tuukkanen, J. and M. Nakamura, Hydroxyapatite as a nanomaterial for advanced tissue engineering and drug therapy. Current Pharmaceutical Design, 2017. 23(26): p. 3786-3793. 66. Albanese, A., P.S. Tang, and W.C. Chan, The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annual review of biomedical engineering, 2012. 14: p. 1-16. 67. Ingato, D., et al., Good things come in small packages: Overcoming challenges to harness extracellular vesicles for therapeutic delivery. Journal of Controlled Release, 2016. 241: p. 174-185. 68. Shyong, Y.-J., et al., Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression. Journal of Controlled Release, 2017. 255: p. 62-72. 69. Ramos, B.P., et al., β2 adrenergic agonist, clenbuterol, enhances working memory performance in aging animals. Neurobiology of aging, 2008. 29(7): p. 1060-1069. 70. Ramos, B.P., et al., The beta-1 adrenergic antagonist, betaxolol, improves working memory performance in rats and monkeys. Biological psychiatry, 2005. 58(11): p. 894-900. 71. McIntyre, C.K., et al., Memory-influencing intra-basolateral amygdala drug infusions modulate expression of Arc protein in the hippocampus. Proceedings of the National Academy of Sciences, 2005. 102(30): p. 10718-10723. 72. Chai, G.-s., et al., Activation of β2-adrenergic receptor promotes dendrite ramification and spine generation in APP/PS1 mice. Neuroscience letters, 2017. 636: p. 158-164. 73. Witherow, D.S., et al., β-Arrestin inhibits NF-κB activity by means of its interaction with the NF-κB inhibitor IκBα. Proceedings of the National Academy of Sciences, 2004. 101(23): p. 8603-8607. 74. Qian, L., et al., β2 Adrenergic receptor activation induces microglial NADPH oxidase activation and dopaminergic neurotoxicity through an ERK‐dependent/protein kinase A‐independent pathway. Glia, 2009. 57(15): p. 1600-1609. 75. Bloebaum, R.D., et al., Dissolution of particulate hydroxyapatite in a macrophage organelle model. Journal of Biomedical Materials Research: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and the Australian Society for Biomaterials, 1998. 40(1): p. 104-114. 76. Walton, J., An aluminum-based rat model for Alzheimer’s disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration. Journal of inorganic biochemistry, 2007. 101(9): p. 1275-1284. 77. Kakkar, V. and I.P. Kaur, Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food and chemical toxicology, 2011. 49(11): p. 2906-2913. 78. Sethi, P., et al., Aluminium-induced electrophysiological, biochemical and cognitive modifications in the hippocampus of aging rats. Neurotoxicology, 2008. 29(6): p. 1069-1079. 79. Thenmozhi, A.J., et al., Neuroprotective effect of hesperidin on aluminium chloride induced Alzheimer’s disease in Wistar rats. Neurochemical research, 2015. 40: p. 767-776. 80. Nittayacharn, P., et al., Increasing doxorubicin loading in lipid-shelled perfluoropropane nanobubbles via a simple deprotonation strategy. Frontiers in pharmacology, 2020. 11: p. 644. 81. Coats, A. and J. Redfern, Thermogravimetric analysis. A review. Analyst, 1963. 88(1053): p. 906-924. 82. Elati, C.R., et al., Polymorphic study of donepezil hydrobromide. 2005. 83. Naiki, H., et al., Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T. Analytical biochemistry, 1989. 177(2): p. 244-249. 84. Abdel-Aal, R.A., A.-A.A. Assi, and B.B. Kostandy, Rivastigmine reverses aluminum-induced behavioral changes in rats. European journal of pharmacology, 2011. 659(2-3): p. 169-176. 85. Morris, R., Developments of a water-maze procedure for studying spatial learning in the rat. Journal of neuroscience methods, 1984. 11(1): p. 47-60. 86. Singh, N.A., et al., EGCG Nanoparticles Attenuate Aluminum Chloride Induced Neurobehavioral Deficits, Beta Amyloid and Tau Pathology in a Rat Model of Alzheimer's Disease. Frontiers in aging neuroscience, 2018. 10: p. 244-244. 87. Huang, S.-M., et al., Differences in brain activity between normal and diabetic rats under isoflurane anesthesia: a resting-state functional MRI study. BMC Medical Imaging, 2022. 22(1): p. 1-8. 88. Zheng, W., et al., Disrupted regional cerebral blood flow, functional activity and connectivity in Alzheimer’s disease: a combined ASL perfusion and resting state fMRI study. Frontiers in Neuroscience, 2019. 13: p. 738. 89. Yang, Y.-G., et al., Pharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers. International journal of clinical and experimental medicine, 2015. 8(10): p. 18744. 90. Brundavanam, R.K., G.E.J. Poinern, and D. Fawcett, Modelling the crystal structure of a 30 nm sized particle based hydroxyapatite powder synthesised under the influence of ultrasound irradiation from X-ray powder diffraction data. American Journal of Materials Science, 2013. 3(4): p. 84-90. 91. Hardi, J. Synthesis of hydroxyapatite from meti shells (batissa violecea l. Von Lamark 1818) by wet precipitation method. in Journal of Physics: Conference Series. 2020. IOP Publishing. 92. Hirota, K. and H. Terada, Endocytosis of particle formulations by macrophages and its application to clinical treatment. Molecular regulation of endocytosis, 2012. 1. 93. Kim, S., et al., Synthesis of Si, Mg substituted hydroxyapatites and their sintering behaviors. Biomaterials, 2003. 24(8): p. 1389-1398. 94. Emken, E.A., Metabolism of dietary stearic acid relative to other fatty acids in human subjects. The American journal of clinical nutrition, 1994. 60(6): p. 1023S-1028S. 95. Toro, R., et al., Structural characterization of a new form of clenbuterol, a well-known decongestant and bronchodilator also used as a performance-enhancing drug. Powder Diffraction, 2013. 28(2): p. 63-67. 96. Li, L., et al., A Broad‐Spectrum ROS‐Eliminating Material for Prevention of Inflammation and Drug‐Induced Organ Toxicity. Advanced science, 2018. 5(10): p. 1800781. 97. Sher, Y.-P. and M.-C. Hung, Blood AST, ALT and urea/BUN level analysis. Bio-protocol, 2013. 3(19): p. e931-e931. 98. Daniel, M., S. Baskar, and M. Latha, Fractal dimension and tertiary structure of proteins. Physica Scripta, 1999. 60(3): p. 270. 99. Fisher, D.J. Directed Synthesis. 2023. Materials Research Forum LLC. 100. Koutsopoulos, S., Synthesis and characterization of hydroxyapatite crystals: a review study on the analytical methods. Journal of Biomedical Materials Research: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials, 2002. 62(4): p. 600-612. 101. Kou, L., et al., The endocytosis and intracellular fate of nanomedicines: Implication for rational design. Asian Journal of Pharmaceutical Sciences, 2013. 8(1): p. 1-10. 102. Jain, P., et al., Designing of Manganese-Based Nanomaterials for Pharmaceutical and Biomedical Applications. Journal of Materials Chemistry B, 2023. 103. Tiwari, S.B., et al., Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. aaps Pharmscitech, 2003. 4(3): p. 18-23. 104. Brockway, J., J. MacRae, and P. Williams, Side effects of clenbuterol as a repartitioning agent. The Veterinary Record, 1987. 120(16): p. 381-383. 105. Alshaikh, R.A., C. Waeber, and K.B. Ryan, Polymer based sustained drug delivery to the ocular posterior segment: Barriers and future opportunities for the treatment of neovascular pathologies. Advanced Drug Delivery Reviews, 2022. 187: p. 114342. 106. Gholami, A., Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches. Neuroscience Letters, 2023: p. 137532. 107. Matuszyk, M.M., et al., Biological and methodological complexities of beta‐amyloid peptide: Implications for Alzheimer’s disease research. Journal of Neurochemistry, 2022. 160(4): p. 434-453. 108. Tao, X., et al., Preparation and drug release study of novel nanopharmaceuticals with polysorbate 80 surface adsorption. Journal of Nanomaterials, 2018. 2018. 109. Asadbegi, M., et al., Investigation of thymol effect on learning and memory impairment induced by intrahippocampal injection of amyloid beta peptide in high fat diet-fed rats. Metabolic brain disease, 2017. 32: p. 827-839. 110. Zhu, Y., et al., Antioxidant peptides, the guardian of life from oxidative stress. Medicinal Research Reviews, 2023. 111. Sokołowska, P., et al., Antidepressant mechanisms of ketamine’s action: NF-κB in the spotlight. Biochemical Pharmacology, 2023: p. 115918. 112. Arnsten, A.F., Y. Ishizawa, and Z. Xie, Scientific rationale for the use of α2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Molecular Psychiatry, 2023: p. 1-13. 113. Introini-Collison, I.B., B. Miyazaki, and J.L. McGaugh, Involvement of the amygdala in the memory-enhancing effects of clenbuterol. Psychopharmacology (Berl), 1991. 104(4): p. 541-4. 114. McIntyre, C.K., et al., Memory-influencing intra-basolateral amygdala drug infusions modulate expression of Arc protein in the hippocampus. Proc Natl Acad Sci U S A, 2005. 102(30): p. 10718-23. 115. Damo, E., A. Agarwal, and M. Simonetti, Activation of β2-adrenergic receptors in microglia alleviates neuropathic hypersensitivity in mice. Cells, 2023. 12(2): p. 284. 116. Montgomery, S.L. and W.J. Bowers, Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. Journal of neuroimmune pharmacology, 2012. 7(1): p. 42-59. 117. Hou, Y., et al., Okanin, effective constituent of the flower tea Coreopsis tinctoria, attenuates LPS-induced microglial activation through inhibition of the TLR4/NF-κB signaling pathways. Scientific reports, 2017. 7(1): p. 45705. 118. Rahman, S.O., et al., Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Abeta peptides in animal model of Alzheimer's disease. Biomed Pharmacother, 2019. 110: p. 47-58. 119. Guglielmotto, M., et al., AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiology of aging, 2012. 33(1): p. 196. e13-196. e27. 120. Chen, C.-H., et al., Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. International Journal of Neuropsychopharmacology, 2012. 15(1): p. 77-90. 121. Lin, Y.W., et al., Investigating a Curcumin-Loaded PLGA-PEG-PLGA Thermo-Sensitive Hydrogel for the Prevention of Alzheimer's Disease. Antioxidants (Basel), 2022. 11(4). | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92663 | - |
dc.description.abstract | 阿茲海默症(AD)是一種複雜的神經退化性疾病,臨床上以認知功能受損為病理特徵。形態學觀察 AD 的主要病因包括由澱粉樣蛋白(Aβ)形成的細胞外澱粉樣蛋白聚集體(斑塊)和高磷酸化Tau 蛋白的細胞內神經原纖維纏結(NFT)的積累。發炎在AD 的發展中起著重要作用。在本研究中,於澱粉樣蛋白(Aβ)假說,證實阿茲海默症是由異常的Aβ 積累引起,Aβ 會引起氧化壓力,發炎反應及神經元功能障礙之間存在關聯。克崙特羅是一種β2 腎上腺素激動劑,具有顯著抗發炎能力。克崙特羅的半衰期短,患者常因記憶力減退忘記服藥而影響治療效果。為提高
藥物生物利用率,本研究利用共沉澱法將多孔氫氧基磷灰石(meso-HAp)合成出100 nm 大小微粒,並以硬脂酸進行表面改質,修飾其疏水性(SHAP),藉由物理吸附將克倫特羅(CLB)負載到SHAP 奈米顆粒上,形成藥物載體系統(SHAPCLB)。此藥物載體一被巨噬細胞吞噬後,由於滲透壓的改變,溶酶體/核內體複合體破裂,導致CLB 釋放到細胞質。然而,由於高濃度鈣離子(Ca2 +)濃度,CLB被胞吐到細胞外空間,並最終達到血液循環。本研究使用SHAP 製備藥物載體攜載克倫特羅,降低克倫特羅被代謝以提高生物利用率,此載體大小約為100 nm,可有效地被巨噬細胞吞噬,同時利用WST-1 證實SHAP-CLB 具有良好之生物相容性,並設計在體外維持兩週之控制釋放。在體外實驗中,證實搭載20 μM 克倫特羅的SHAP 奈米顆粒可有效調節炎症,包括抑制轉錄因子NF-κB 的作用以及抑 制促炎細胞因子和趨化因子的產生,例如腫瘤壞死因子-α 和介白素及降低Aβ 寡聚體引起的毒性,防止蛋白質聚集。在動物實驗中,利用70 mg/kg 氯化鋁誘導動物模型,將載體注射至細胞活性高的肌肉組織,以細胞吞噬藥物的特性來達到恆定釋放的目的。fMRI 結果顯示可有效降地大鼠的神經退化情形、MWM 結果證實改善記憶能力。組織切片進行H&E 染色及BACE1、6E10 抗體的免疫組織染色,並以光學和共焦顯微鏡觀察切片。分別以西方墨點法和液相層析串聯質譜儀(LCMS/MS)評估克倫特羅的治療效率及藥物動力學。以SHAP-CLB 治療8 週後,測得大鼠大腦中克倫特羅濃度為2.38 ng/mL,上述結果證實載藥載體具有良好防止阿茲海默症之功效。研究結果顯示,SHAP 遞送克崙特羅的藥物控制釋放系統對於AD 治療有臨床上之治療潛力。 | zh_TW |
dc.description.abstract | Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized clinically by impaired cognitive function. Morphological observations of AD reveal the accumulation of extracellular amyloid-beta (Aβ) fibrillar aggregates (plaques) and intracellular neurofibrillary tangles (NFT) formed by hyperphosphorylated Tau protein as major pathological features. Inflammation plays a crucial role in the development of AD. In this study, based on the Aβ hypothesis, Alzheimer's disease is confirmed to result from abnormal Aβ accumulation, leading to oxidative stress, inflammatory responses, and neuronal dysfunction. Clenbuterol is a β2-adrenergic agonist, exhibits significant anti-inflammatory capabilities. However, its short half-life often leads to treatment inefficacy due to patients forgetting to take the medication. To enhance drug bioavailability, this research utilized a co-precipitation method to synthesize porous hydroxyapatite (mesoHAp) particles of approximately 100 nm. Surface modification using stearic acid improved its hydrophobicity (SHAP). Clenbuterol (CLB) was physically adsorbed onto SHAP nanoparticles, forming a drug delivery system (SHAP-CLB). Once engulfed by macrophages, changes in osmotic pressure cause lysosome/endosome complex rupture, releasing CLB into the cytoplasm. However, due to high concentrations of calcium ions (Ca2+), CLB is expelled into the extracellular space, eventually reaching the bloodstream. This study employed SHAP to prepare a drug carrier for transporting chloroquine, reducing its metabolism to enhance bioavailability. The carrier, with a size of approximately 100 nm, is efficiently phagocytosed by macrophages. WST-1 assays confirmed the good biocompatibility of SHAP-CLB, with controlled release maintained for two weeks in vitro. In vitro experiments demonstrated that SHAP nanoparticles loaded with 20 µM chloroquine effectively modulated inflammation by inhibiting transcription factor NF-κB and suppressing the production of pro-inflammatory cytokines and chemokines, such as tumor necrosis factor-α and interleukins, while reducing the toxicity induced by Aβ oligomers and preventing protein aggregation. In animal experiments using a 70 mg/kg aluminum chloride-induced model, the carrier was injected into highly active muscle tissue to achieve sustained release through cellular phagocytosis. fMRI results showed effective reduction in neurodegeneration in rats, and Morris Water Maze results confirmed improved memory capacity. Tissue sections were stained with H&E and immunohistochemistry using BACE1 and 6E10 antibodies, observed through optical and confocal microscopy. The therapeutic efficiency and pharmacokinetics of chloroquine were evaluated using Western blotting and liquid chromatography-tandem mass spectrometry (LC-MS/MS). After 8 weeks of SHAP-CLB treatment, the chloroquine concentration in the rat brain was measured at 2.38 ng/mL, confirming the efficacy of the drug-loaded carrier in preventing Alzheimer's disease. The research results suggest that the SHAP-delivered chloroquine drug control release system has clinical potential for AD treatment. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-05-31T16:06:44Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2024-05-31T16:06:44Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員會審定書 ........................................................................................................... i
誌謝 .................................................................................................................................. ii 中文摘要 ......................................................................................................................... iii ABSTRACT ..................................................................................................................... v CONTENTS .................................................................................................................. viii LIST OF FIGURES....................................................................................................... xiv LIST OF TABLES ...................................................................................................... xviii LIST OF ABBREVIATION.......................................................................................... xix Chapter 1. INTRODUCTION.................................................................................... 1 1.1 Background......................................................................................................... 1 1.2 Alzheimer’s disease............................................................................................ 3 1.2.1 Stages and Symptoms of AD................................................................... 3 1.2.2 AD Pathophysiology (Aβ-Induced Neuronal Dysfunction) .................... 5 1.3 Hypothesis of Pathogenesis ................................................................................ 8 1.3.1 The Cholinergic Hypothesis .................................................................... 9 1.3.2 The Tau Protein Cascade Hypothesis .................................................... 10 1.3.3 The Amyloid Cascade Hypothesis ........................................................ 15 1.3.4 The Inflammation Hypothesis ............................................................... 19 1.4 Microglial Ontogeny and Phenotypic Diversity............................................... 25 1.5 Drugs for AD Treatment................................................................................... 30 1.5.1 Current Drugs ........................................................................................ 30 1.5.2 -Secretase Inhibitors ............................................................................ 31 1.5.3 A Aggregation Inhibitors..................................................................... 33 1.5.4 A Vaccines .......................................................................................... 35 1.5.5 Drugs Targeting Inflammation .............................................................. 35 1.6 Purpose of the Study......................................................................................... 38 Chapter 2. THEORETICAL BASIS............................................................................ 41 2.1 Hydroxyapatite (HAp)...................................................................................... 41 2.1.1 Structure of HAp ................................................................................... 41 2.1.2 Potential of HAp as a Drug Carrier ....................................................... 42 2.1.3 Crafting Ceramic Nanoparticles for Targeted Drug Delivery ............... 43 2.1.4 Overcoming Challenges in Therapeutic Delivery ................................. 44 2.1.5 Innovative Solution: mesoHAp ............................................................. 45 2.2 Clenbuterol (CLB) ............................................................................................ 45 2.2.1 Activation of β2-AR for AD Therapy ................................................... 47 2.2.2 Anti-Inflammatory Effects of CLB ....................................................... 48 2.3 The Principle of Intracellular Delivery of SHAP-CLB.................................... 50 2.4 The Animal Model of AD ................................................................................ 52 Chapter 3. MATERIALS AND METHODS ........................................................... 55 3.1 Experimental Instrument .................................................................................. 56 3.2 Materials ........................................................................................................... 57 3.3 Synthesis of mesoHAp ..................................................................................... 58 3.4 Preparation of Hydrophobic CLB .................................................................... 59 3.5 Surface Modification of meso-HAp for Hydrophobicity and CLB Loading ... 60 3.6 Synthesis and Observation of Aβ Fibrils .......................................................... 60 3.7 Characterization................................................................................................ 61 3.7.1 XRD Analysis of SHAP-CLB............................................................... 61 3.7.2 FTIR Analysis of SHAP-CLB............................................................... 62 3.7.3 Morphology and Surface Characteristics of SHAP-CLB...................... 62 3.8 Drug Loading Capacity .................................................................................... 63 3.9 In Vitro CLB Release Profile............................................................................ 64 3.10 Inhibition of Aβ Aggregation by CLB ........................................................... 65 3.11 ThT Fluorescence Assay for Monitoring Aβ Aggregation............................. 65 3.12 Biocompatibility of SHAP-CLB .................................................................... 66 3.13 Visualizing SHAP-CLB Internalization by RAW-264.7 Cells ...................... 67 3.14 Phagocytosis of Particles and Cellular Uptake by RAW-264.7 Cells............ 68 3.15 Western Blot Analysis of SHAP-CLB Inhibition of LPS-Induced Inflammation ................................................................................................................................ 69 3.16 Cytokine Quantification in LPS-Induced Inflammation by ELISA............... 70 3.17 Animal Study.................................................................................................. 70 3.18 Morris Water Maze (MWM).......................................................................... 72 3.19 functional Magnetic Resonance Imaging (fMRI)........................................... 73 3.20 Pharmacokinetic Study of CLB by Liquid Chromatography-Mass Spectrometry (LC-MS/MS) .......................................................................................................... 74 3.21 Histological Analysis and Immunohistochemical Staining............................ 75 3.22 Statistical Analysis ......................................................................................... 76 Chapter 4. RESULTS............................................................................................... 77 4.1 Characterization of SHAP-CLB....................................................................... 77 4.1.1 Crystal Phase Identification of SHAP-CLB.......................................... 77 4.1.2 Function Group Identification ............................................................... 78 4.1.3 Morphology of SHAP-CLB .................................................................. 80 4.1.4 Surface Area Analysis Using BET Analysis ......................................... 83 4.1.5 1H NMR Spectrum of CLB ................................................................... 85 4.2 Drug-Loading Efficiency of SHAP-CLB......................................................... 86 4.3 Drug Release Profile of SHAP-CLB................................................................ 87 4.4 Efficiency of CLB to Inhibit Aβ Aggregation.................................................. 90 4.4.1 TEM for Inhibition of Aβ Aggregation ................................................. 90 4.4.2 ThT Stain for Inhibition of Aβ Aggregation ......................................... 91 4.5 Biocompatibility of SHAP-CLB ...................................................................... 94 4.6 Phagocytosis of SHAP-CLB Particles by RAW-264.7 Cells........................... 95 4.6.1 Cellular Uptake and Release Mechanism of SHAP-CLB ..................... 95 4.6.2 Release Mechanism of SHAP-CLB using TEM Observation............... 98 4.7 Inhibitory Effect of SHAP-CLB on LPS-Induced Inflammatory Mediators in BV-2 Microglial Cells .......................................................................................... 100 4.8 MWM Test of SHAP-CLB Particles .............................................................. 102 4.9 Determination of Hippocampal Activity by Resting State fMRI (rs-fMRI) Index .............................................................................................................................. 104 4.10 Pharmacokinetics of CLB............................................................................. 105 4.11 Determination of Sub-Chronic and Chronic Toxicity [97] .......................... 110 4.12 Histological Analysis.................................................................................... 112 4.13 Therapeutic Effect of SHAP-CLB in AD Rats............................................. 115 Chapter 5. DISCUSSION....................................................................................... 118 Chapter 6. CONCLUSION .................................................................................... 130 REFERENCE ............................................................................................................... 131 PUBLICATION LIST.................................................................................................. 150 | - |
dc.language.iso | en | - |
dc.title | 以多孔性氫氧基磷灰石作為克崙特羅之藥物控制釋放載體以治療阿茲海默症 | zh_TW |
dc.title | Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer’s Disease | en |
dc.type | Thesis | - |
dc.date.schoolyear | 112-2 | - |
dc.description.degree | 博士 | - |
dc.contributor.oralexamcommittee | 吳造中;黃義侑;郭士民;姚俊旭 | zh_TW |
dc.contributor.oralexamcommittee | Chau-Chung Wu;Yi-You Huang;Shyh-Ming Kuo;Chun-Hsu Yao | en |
dc.subject.keyword | 阿茲海默症,β澱粉樣蛋白,克崙特羅,氫氧基磷灰石,藥物控制系統, | zh_TW |
dc.subject.keyword | Alzheimer's disease,β-amyloid,clenbuterol,hydroxyapatite,drug delivery system, | en |
dc.relation.page | 153 | - |
dc.identifier.doi | 10.6342/NTU202304507 | - |
dc.rights.note | 同意授權(限校園內公開) | - |
dc.date.accepted | 2023-12-13 | - |
dc.contributor.author-college | 工學院 | - |
dc.contributor.author-dept | 醫學工程學系 | - |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-112-2.pdf 目前未授權公開取用 | 5.9 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。